Noroviruses: Epidemiology, immunity and prospects for prevention

Future Microbiology

Volumn 10, Issue 1, 2015, Pages 53-67

  Pringle, Kimberly ^a,b   Lopman, Benjamin ^a   Vega, Everardo ^a   Vinje, Jan ^a   Parashar, Umesh D ^a   Hall, Aron J ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Caliciviridae; GII.4; herd immunity; norovirus; vaccine

Indexed keywords

NOROVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

CLINICAL FEATURE; EPIDEMIC; HUMAN; INFECTION PREVENTION; MOLECULAR EPIDEMIOLOGY; MOLECULAR EVOLUTION; NONHUMAN; NOROVIRUS; NOROVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; VACCINE PRODUCTION; VIRAL GASTROENTERITIS; VIROLOGY; VIRUS CELL INTERACTION; VIRUS DIAGNOSIS; VIRUS IMMUNITY; VIRUS LOAD; VIRUS SHEDDING; VIRUS TRANSMISSION; CALICIVIRIDAE INFECTIONS; GASTROENTERITIS; GENETICS; GENOTYPE; IMMUNOLOGY; PHYSIOLOGY; PREVALENCE; TRANSMISSION;

CALICIVIRIDAE; NOROVIRUS;

CALICIVIRIDAE INFECTIONS; DISEASE OUTBREAKS; GASTROENTERITIS; GENOTYPE; HUMANS; MOLECULAR EPIDEMIOLOGY; NOROVIRUS; PREVALENCE; VIRAL VACCINES;

EID: 84921524909     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.14.102     Document Type: Review

References (155)

1. Kapikian AZ, Wyatt RG, Dolin R, Thornhill TS, Kalica AR, Chanock RM. Visualization by immune electron microscopy of a 27-nm particle associated with acute infectious nonbacterial gastroenteritis. J. Virol. 10(5), 1075-1081 (1972).
2. Kapikian AZ. The discovery of the 27-nm Norwalk virus: an historic perspective. J. Infect. Dis. 181(Suppl. 2), S295-S302 (2000).
3. Viruses ICoTo. Virus taxonomy. www.ictvonline.org/virusTaxonomy.asp
4. Kroneman A, Vega E, Vennema H et al. Proposal for a unified norovirus nomenclature and genotyping. Arch. Virol. 158(10), 2059-2068 (2013).
5. University of California San Francisco Chimera: an extensible molecular modeling system. http://www.cgl.ucsf.edu/chimera/
6. Kirby A, Gurgel RQ, Dove W, Vieira SC, Cunliffe NA, Cuevas LE. An evaluation of the RIDASCREEN and IDEIA enzyme immunoassays and the RIDAQUICK immunochromatographic test for the detection of norovirus in faecal specimens. J. Clin. Virol. 49(4), 254-257 (2010).
7. Morillo SG, Luchs A, Cilli A et al. Norovirus 3rd generation kit: an improvement for rapid diagnosis of sporadic gastroenteritis cases and valuable for outbreak detection. J. Virol. Methods 173(1), 13-16 (2011).
8. Derrington P, Schreiber F, Day S, Curtis C, Lyon M. Norovirus Ridaquick: a new test for rapid diagnosis of norovirus. Pathology 41(7), 687-688 (2009).
9. Bruins MJ, Wolfhagen MJ, Schirm J, Ruijs GJ. Evaluation of a rapid immunochromatographic test for the detection of norovirus in stool samples. Eur. J. Clin. Microbiol. Infect. Dis. 29(6), 741-743 (2010).
10. Gray JJ, Kohli E, Ruggeri FM et al. European multicenter evaluation of commercial enzyme immunoassays for detecting norovirus antigen in fecal samples. Clin. Vaccine Immunol. 14(10), 1349-1355 (2007).
11. Atmar RL, Estes MK. The epidemiologic and clinical importance of norovirus infection. Gastroenterol. Clin. North Am. 35(2), 275-290 (2006).
12. Rockx B, De Wit M, Vennema H et al. Natural history of human calicivirus infection: a prospective cohort study. Clin. Infect. Dis. 35(3), 246-253 (2002).
13. Grmek Kosnik I, Peternelj B, Pohar M, Kraigher A. Outbreak of norovirus infection in a nursing home in northern Slovenia, July 2007. Euro Surveill. 12(10), E071011.3 (2007).
14. Lopman BA, Reacher MH, Vipond IB, Sarangi J, Brown DW. Clinical manifestation of norovirus gastroenteritis in health care settings. Clin. Infect. Dis. 39(3), 318-324 (2004).
15. Harris JP, Edmunds WJ, Pebody R, Brown DW, Lopman BA. Deaths from norovirus among the elderly, England and Wales. Emerg. Infect. Dis. 14(10), 1546-1552 (2008).
16. Schwartz S, Vergoulidou M, Schreier E et al. Norovirus gastroenteritis causes severe and lethal complications after chemotherapy and hematopoietic stem cell transplantation. Blood 117(22), 5850-5856 (2011).
17. Trivedi TK, DeSalvo T, Lee L et al. Hospitalizations and mortality associated with norovirus outbreaks in nursing homes, 2009-2010. JAMA 308(16), 1668-1675 (2012).
18. Desai R, Hembree CD, Handel A et al. Severe outcomes are associated with genogroup 2 genotype 4 norovirus outbreaks: a systematic literature review. Clin. Infect. Dis. 55(2), 189-193 (2012).
19. Hall AJ, Curns AT, McDonald LC, Parashar UD, Lopman BA. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin. Infect. Dis. 55(2), 216-223 (2012).
20. Atmar RL, Opekun AR, Gilger MA et al. Norwalk virus shedding after experimental human infection. Emerg. Infect. Dis. 14(10), 1553-1557 (2008).
21. Phillips G, Lopman B, Tam CC, Iturriza-Gomara M, Brown D, Gray J. Diagnosing norovirus-associated infectious intestinal disease using viral load. BMC Infect. Dis. 9, 63 (2009).
22. Murata T, Katsushima N, Mizuta K, Muraki Y, Hongo S, Matsuzaki Y. Prolonged norovirus shedding in infants < or = 6 months of age with gastroenteritis. Pediatr. Infect. Dis. J. 26(1), 46-49 (2007).
23. Siebenga JJ, Beersma MF, Vennema H, van Biezen P, Hartwig NJ, Koopmans M. High prevalence of prolonged norovirus shedding and illness among hospitalized patients: a model for in vivo molecular evolution. J. Infect. Dis. 198(7), 994-1001 (2008).
24. Lai CC, Wang YH, Wu CY, Hung CH, Jiang DD, Wu FT. A norovirus outbreak in a nursing home: norovirus shedding time associated with age. J. Clin. Virol. 56(2), 96-101 (2013).
25. Svraka S, Duizer E, Vennema H et al. Etiological role of viruses in outbreaks of acute gastroenteritis in The Netherlands from 1994 through 2005. J. Clin. Microbiol. 45(5), 1389-1394 (2007).
26. Bucardo F, Nordgren J, Carlsson B et al. Pediatric norovirus diarrhea in Nicaragua. J. Clin. Microbiol. 46(8), 2573-2580 (2008).
27. Amar CF, East CL, Gray J, Iturriza-Gomara M, Maclure EA, McLauchlin J. Detection by PCR of eight groups of enteric pathogens in 4627 faecal samples: re-examination of the English case-control Infectious Intestinal Disease Study (1993-1996). Eur. J. Clin. Microbiol. Infect. Dis. 26(5), 311-323 (2007).
28. Barreira DM, Ferreira MS, Fumian TM et al. Viral load and genotypes of noroviruses in symptomatic and asymptomatic children in Southeastern Brazil. J. Clin. Virol. 47(1), 60-64 (2010).
29. Teunis PF, Moe CL, Liu P et al. Norwalk virus: how infectious is it? J. Med Virol. 80(8), 1468-1476 (2008).
30. Atmar RL, Opekun AR, Gilger MA et al. Determination of the 50% human infectious dose for norwalk virus. J. Infect. Dis. 209(7), 1016-1022 (2014).
31. Chan MC, Sung JJ, Lam RK et al. Fecal viral load and norovirus-associated gastroenteritis. Emerg. Infect. Dis. 12(8), 1278-1280 (2006).
32. Lopman B, Gastanaduy P, Park GW, Hall AJ, Parashar UD, Vinje J. Environmental transmission of norovirus gastroenteritis. Curr. Opin. Virol. 2(1), 96-102 (2012).
33. Patel MM, Hall AJ, Vinje J, Parashar UD. Noroviruses: a comprehensive review. J. Clin. Virol. 44(1), 1-8 (2009).
34. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention. Updated norovirus outbreak management and disease prevention guidelines. MMWR Recomm. Rep. 60(RR-3), 1-18 (2011).
35. Vega E, Barclay L, Gregoricus N, Shirley SH, Lee D, Vinje J. Genotypic and epidemiologic trends of norovirus outbreaks in the United States, 2009 to 2013. J. Clin. Microbiol. 52(1), 147-155 (2014).
36. Hall AJ, Wikswo ME, Manikonda K, Roberts VA, Yoder JS, Gould LH. Acute gastroenteritis surveillance through the National Outbreak Reporting System, United States. Emerg. Infect. Dis. 19(8), 1305-1309 (2013).
37. Maunula L, Von Bonsdorff CH. Norovirus genotypes causing gastroenteritis outbreaks in Finland 1998-2002. J. Clin. Virol. 34(3), 186-194 (2005).
38. Bernard H, Hohne M, Niendorf S, Altmann D, Stark K. Epidemiology of norovirus gastroenteritis in Germany 2001-2009: eight seasons of routine surveillance. Epidemiol. Infect. 142(1), 63-74 (2014).
39. Lopman BA, Adak GK, Reacher MH, Brown DW. Two epidemiologic patterns of norovirus outbreaks: surveillance in England and wales, 1992-2000. Emerg. Infect. Dis. 9(1), 71-77 (2003).
40. Marshall JA, Dimitriadis A, Wright PJ. Molecular and epidemiological features of norovirus-associated gastroenteritis outbreaks in Victoria, Australia in 2001. J. Med. Virol. 75(2), 321-331 (2005).
41. Buesa J, Collado B, Lopez-Andujar P et al. Molecular epidemiology of caliciviruses causing outbreaks and sporadic cases of acute gastroenteritis in Spain. J. Clin. Microbiol. 40(8), 2854-2859 (2002).
42. Matthews JE, Dickey BW, Miller RD et al. The epidemiology of published norovirus outbreaks: a review of risk factors associated with attack rate and genogroup. Epidemiol. Infect. 140(7), 1161-1172 (2012).
43. Trainor E, Lopman B, Iturriza-Gomara M et al. Detection and molecular characterisation of noroviruses in hospitalised children in Malawi, 1997-2007. J. Med. Virol. 85(7), 1299-1306 (2013).
44. Dey SK, Phathammavong O, Okitsu S, Mizuguchi M, Ohta Y, Ushijima H. Seasonal pattern and genotype distribution of norovirus infection in Japan. Pediatr. Infect. Dis. J. 29(5), e32-e34 (2010).
45. Monica B, Ramani S, Banerjee I et al. Human caliciviruses in symptomatic and asymptomatic infections in children in Vellore, South India. J. Med. Virol. 79(5), 544-551 (2007).
46. Iturriza Gomara M, Simpson R, Perault AM et al. Structured surveillance of infantile gastroenteritis in East Anglia, UK: incidence of infection with common viral gastroenteric pathogens. Epidemiol. Infect. 136(1), 23-33 (2008).
47. Estevez A, Arvelo W, Hall AJ et al. Prevalence and genetic diversity of norovirus among patients with acute diarrhea in Guatemala. J. Med. Virol. 85(7), 1293-1298 (2013).
48. Saito M, Goel-Apaza S, Espetia S et al. Multiple norovirus infections in a birth cohort in a Peruvian Periurban community. Clin. Infect. Dis. 58(4), 483-491 (2014).
49. El Qazoui M, Oumzil H, Baassi L et al. Rotavirus and norovirus infections among acute gastroenteritis children in Morocco. BMC Infect. Dis. 14, 300 (2014).
50. Ahmed SM, Hall AJ, Robinson AE et al. Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis. Lancet Infect. Dis. 14(8), 725-730 (2014).
51. Zheng DP, Widdowson MA, Glass RI, Vinje J. Molecular epidemiology of genogroup II-genotype 4 noroviruses in the United States between 1994 and 2006. J. Clin. Microbiol. 48(1), 168-177 (2010).
52. Lindell AT, Grillner L, Svensson L, Wirgart BZ. Molecular epidemiology of norovirus infections in Stockholm, Sweden, during the years 2000 to 2003: association of the GGIIb genetic cluster with infection in children. J. Clin. Microbiol. 43(3), 1086-1092 (2005).
53. Hasing ME, Lee BE, Preiksaitis JK et al. Emergence of a new norovirus GII.4 variant and changes in the historical biennial pattern of norovirus outbreak activity in Alberta, Canada, from 2008 to 2013. J. Clin. Microbiol. 51(7), 2204-2211 (2013).
54. Fonager J, Hindbaek LS, Fischer TK. Rapid emergence and antigenic diversification of the norovirus 2012 Sydney variant in Denmark, October to December, 2012. Euro Surveill. 18(9) 20413 (2013).
55. Noel JS, Fankhauser RL, Ando T, Monroe SS, Glass RI. Identification of a distinct common strain of 'Norwalk-like viruses' having a global distribution. J. Infect. Dis. 179(6), 1334-1344 (1999).
56. Lopman B, Vennema H, Kohli E et al. Increase in viral gastroenteritis outbreaks in Europe and epidemic spread of new norovirus variant. Lancet 363(9410), 682-688 (2004).
57. Vinje J, Altena SA, Koopmans MP. The incidence and genetic variability of small round-structured viruses in outbreaks of gastroenteritis in The Netherlands. J. Infect. Dis. 176(5), 1374-1378 (1997).
58. Yen C, Wikswo ME, Lopman BA, Vinje J, Parashar UD, Hall AJ. Impact of an emergent norovirus variant in 2009 on norovirus outbreak activity in the United States. Clin. Infect. Dis. 53(6), 568-571 (2011).
59. Leshem E, Wikswo M, Barclay L et al. Effects and clinical significance of GII.4 Sydney norovirus, United States, 2012-2013. Emerg. Infect. Dis. 19(8), 1231-1238 (2013).
60. Siebenga JJ, Vennema H, Zheng DP et al. Norovirus illness is a global problem: emergence and spread of norovirus GII.4 variants, 2001-2007. J. Infect. Dis. 200(5), 802-812 (2009).
61. Siebenga JJ, Vennema H, Renckens B et al. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. J. Virol. 81(18), 9932-9941 (2007).
62. Koopmans M. Noroviruses in healthcare settings: a challenging problem. J. Hosp. Infect. 73(4), 331-337 (2009).
63. Okada M, Tanaka T, Oseto M, Takeda N, Shinozaki K. Genetic analysis of noroviruses associated with fatalities in healthcare facilities. Arch. Virol. 151(8), 1635-1641 (2006).
64. Sakon N, Yamazaki K, Yoda T et al. Norovirus storm in Osaka, Japan, last winter (2006/2007). Jpn J. Infect. Dis. 60(6), 409-410 (2007).
65. Verhoef LP, Kroneman A, van Duynhoven Y et al. Selection tool for foodborne norovirus outbreaks. Emerg. Infect. Dis. 15(1), 31-38 (2009).
66. Bitler EJ, Matthews JE, Dickey BW, Eisenberg JN, Leon JS. Norovirus outbreaks: a systematic review of commonly implicated transmission routes and vehicles. Epidemiol. Infect. 141(8), 1563-1571 (2013).
67. Mai H, Jin M, Guo X et al. Clinical and epidemiologic characteristics of norovirus GII.4 Sydney during winter 2012-13 in Beijing, China following its global emergence. PLoS ONE 8(8), e71483 (2013).
68. Friesema IH, Vennema H, Heijne JC et al. Differences in clinical presentation between norovirus genotypes in nursing homes. J. Clin. Virol. 46(4), 341-344 (2009).
69. Nahar S, Afrad MH, Fahmi T et al. A novel norovirus recombinant strain GII.4/GII.21 in Bangladesh, 2011. Virus Genes 46(3), 538-541 (2013).
70. Abugalia M, Cuevas L, Kirby A et al. Clinical features and molecular epidemiology of rotavirus and norovirus infections in Libyan children. J. Med. Virol. 83(10), 1849-1856 (2011).
71. Payne DC, Vinje J, Szilagyi PG et al. Norovirus and medically attended gastroenteritis in U.S. children. N. Engl. J. Med. 368(12), 1121-1130 (2013).
72. Zhang S, Chen TH, Wang J et al. Symptomatic and asymptomatic infections of rotavirus, norovirus, and adenovirus among hospitalized children in Xi'an, China. J. Med. Virol. 83(8), 1476-1484 (2011).
73. Cheng WX, Ye XH, Yang XM et al. Epidemiological study of human calicivirus infection in children with gastroenteritis in Lanzhou from 2001 to 2007. Arch. Virol. 155(4), 553-555 (2010).
74. Mans J, de Villiers JC, du Plessis NM, Avenant T, Taylor MB. Emerging norovirus GII.4 2008 variant detected in hospitalised paediatric patients in South Africa. J. Clin. Virol. 49(4), 258-264 (2010).
75. So CW, Kim DS, Yu ST, Cho JH, Kim JD. Acute viral gastroenteritis in children hospitalized in Iksan, Korea during December 2010-June 2011. Korean J. Pediatr. 56(9), 383-388 (2013).
76. Chhabra P, Dhongade RK, Kalrao VR, Bavdekar AR, Chitambar SD. Epidemiological, clinical, and molecular features of norovirus infections in western India. J. Med. Virol. 81(5), 922-932 (2009).
77. Ren Z, Kong Y, Wang J, Wang Q, Huang A, Xu H. Etiological study of enteric viruses and the genetic diversity of norovirus, sapovirus, adenovirus, and astrovirus in children with diarrhea in Chongqing, China. BMC Infect. Dis. 13, 412 (2013).
78. Ahmed SM, Lopman BA, Levy K. A systematic review and meta-analysis of the global seasonality of norovirus. PLoS ONE 8(10), e75922 (2013).
79. Yang SY, Hwang KP, Wu FT et al. Epidemiology and clinical peculiarities of norovirus and rotavirus infection in hospitalized young children with acute diarrhea in Taiwan, 2009. J. Microbiol. Immunol. Infect. 43(6), 506-514 (2010).
80. Sdiri-Loulizi K, Gharbi-Khelifi H, de Rougemont A et al. Acute infantile gastroenteritis associated with human enteric viruses in Tunisia. J. Clin. Microbiol. 46(4), 1349-1355 (2008).
81. Kabayiza JC, Andersson ME, Nilsson S, Bergström T, Muhirwa G, Lindh M. Real-time PCR Identification of Agents Causing Diarrhea in Rwandan Children Less Than 5 Years of Age.. Pediatr. Infect. Dis. J. 33(10), 1037-1042 (2014).
82. Räsänen S, Lappalainen S, Salminen M, Huhti L, Vesikari T. Noroviruses in children seen in a hospital for acute gastroenteritis in Finland. Eur. J. Pediatr. 170(11), 1413-1418 (2011).
83. PATH. Country introductions of rotavirus vaccines. http://sites.path.org/rotavirusvaccine/country
84. Wikswo ME, Desai R, Edwards KM et al. Clinical profile of children with norovirus disease in rotavirus vaccine era. Emerg. Infect. Dis. 19(10), 1691-1693 (2013).
85. Pang XL, Joensuu J, Vesikari T. Human calicivirus-associated sporadic gastroenteritis in Finnish children less than two years of age followed prospectively during a rotavirus vaccine trial. Pediatr. Infect. Dis. J. 18(5), 420-426 (1999).
86. World Health Organization. Treatment of diarrhoea: a manual for physicians and senior health workers. http://whqlibdoc.who.int/publications
87. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand. J. Infect. Dis. 22(3), 259-267 (1990).
88. Farkas T, Jiang X, Guerrero ML et al. Prevalence and genetic diversity of human caliciviruses (HuCVs) in Mexican children. J. Med. Virol. 62(2), 217-223 (2000).
89. Gutierrez-Escolano AL, Velazquez FR, Escobar-Herrera J, Lopez Saucedo C, Torres J, Estrada-Garcia T. Human caliciviruses detected in Mexican children admitted to hospital during 1998-2000, with severe acute gastroenteritis not due to other enteropathogens. J. Med. Virol. 82(4), 632-637 (2010).
90. Hoa Tran TN, Trainor E, Nakagomi T, Cunliffe NA, Nakagomi O. Molecular epidemiology of noroviruses associated with acute sporadic gastroenteritis in children: global distribution of genogroups, genotypes and GII.4 variants. J. Clin. Virol. 56(3), 185-193 (2013).
91. Huhti L, Szakal ED, Puustinen L et al. Norovirus GII-4 causes a more severe gastroenteritis than other noroviruses in young children. J. Infect. Dis. 203(10), 1442-1444 (2011).
92. Ayukekbong J, Lindh M, Nenonen N, Tah F, Nkuo-Akenji T, Bergstrom T. Enteric viruses in healthy children in Cameroon: viral load and genotyping of norovirus strains. J. Med. Virol. 83(12), 2135-2142 (2011).
93. Mattison K, Sebunya TK, Shukla A, Noliwe LN, Bidawid S. Molecular detection and characterization of noroviruses from children in Botswana. J. Med. Virol. 82(2), 321-324 (2010).
94. Lindesmith L, Moe C, Marionneau S et al. Human susceptibility and resistance to Norwalk virus infection. Nat. Med. 9(5), 548-553 (2003).
95. Lopman B, Simmons K, Gambhir M, Vinje J, Parashar U. Epidemiologic implications of asymptomatic reinfection: a mathematical modeling study of norovirus. Am. J. Epidemiol. 179(4), 507-512 (2014).
96. Bull RA, Eden JS, Rawlinson WD, White PA. Rapid evolution of pandemic noroviruses of the GII.4 lineage. PLoS Pathog. 6(3), e1000831 (2010).
97. Bull RA, White PA. Mechanisms of GII.4 norovirus evolution. Trends Microbiol. 19(5), 233-240 (2011).
98. Tan M, Huang P, Meller J, Zhong W, Farkas T, Jiang X. Mutations within the P2 domain of norovirus capsid affect binding to human histo-blood group antigens: evidence for a binding pocket. J. Virol. 77(23), 12562-12571 (2003).
99. Chen R, Neill JD, Noel JS et al. Inter-and intragenus structural variations in caliciviruses and their functional implications. J. Virol. 78(12), 6469-6479 (2004).
100. Lindesmith LC, Donaldson EF, Lobue AD et al. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med. 5(2), e31 (2008).
101. Boon D, Mahar JE, Abente EJ et al. Comparative evolution of GII.3 and GII.4 norovirus over a 31-year period. J. Virol. 85(17), 8656-8666 (2011).
102. Debbink K, Lindesmith LC, Donaldson EF et al. Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. J. Infect. Dis. 208(11), 1877-1887 (2013).
103. Lindesmith LC, Costantini V, Swanstrom J et al. Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes. J. Virol. 87(5), 2803-2813 (2013).
104. Parrino TA, Schreiber DS, Trier JS, Kapikian AZ, Blacklow NR. Clinical immunity in acute gastroenteritis caused by Norwalk agent. N. Engl. J. Med. 297(2), 86-89 (1977).
105. Baron RC, Greenberg HB, Cukor G, Blacklow NR. Serological responses among teenagers after natural exposure to Norwalk virus. J. Infect. Dis. 150(4), 531-534 (1984).
106. Koopman JS, Eckert EA, Greenberg HB, Strohm BC, Isaacson RE, Monto AS. Norwalk virus enteric illness acquired by swimming exposure. Am. J. Epidemiol. 115(2), 173-177 (1982).
107. Tan M, Jiang X. Norovirus and its histo-blood group antigen receptors: an answer to a historical puzzle. Trends Microbiol. 13(6), 285-293 (2005).
108. Hutson AM, Atmar RL, Graham DY, Estes MK. Norwalk virus infection and disease is associated with ABO histo-blood group type. J. Infect. Dis. 185(9), 1335-1337 (2002).
109. Marionneau S, Ruvoen N, Le Moullac-Vaidye B et al. Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology 122(7), 1967-1977 (2002).
110. Tan M, Jin M, Xie H, Duan Z, Jiang X, Fang Z. Outbreak studies of a GII-3 and a GII-4 norovirus revealed an association between HBGA phenotypes and viral infection. J. Med. Virol. 80(7), 1296-1301 (2008).
111. Thorven M, Grahn A, Hedlund KO et al. A homozygous nonsense mutation (428G->A) in the human secretor (FUT2) gene provides resistance to symptomatic norovirus (GGII) infections. J. Virol. 79(24), 15351-15355 (2005).
112. Bucardo F, Kindberg E, Paniagua M et al. Genetic susceptibility to symptomatic norovirus infection in Nicaragua. J. Med. Virol. 81(4), 728-735 (2009).
113. Tan M, Hegde RS, Jiang X. The P domain of norovirus capsid protein forms dimer and binds to histo-blood group antigen receptors. J. Virol. 78(12), 6233-6242 (2004).
114. Chakravarty S, Hutson AM, Estes MK, Prasad BV. Evolutionary trace residues in noroviruses: importance in receptor binding, antigenicity, virion assembly, and strain diversity. J. Virol. 79(1), 554-568 (2005).
115. Tan M, Xia M, Chen Y et al. Conservation of carbohydrate binding interfaces: evidence of human HBGA selection in norovirus evolution. PLoS ONE 4(4), e5058 (2009).
116. Donaldson EF, Lindesmith LC, Lobue AD, Baric RS. Viral shape-shifting: norovirus evasion of the human immune system. Nat. Rev. Microbiol. 8(3), 231-241 (2010).
117. Fankhauser RL, Monroe SS, Noel JS et al. Epidemiologic and molecular trends of 'Norwalk-like viruses' associated with outbreaks of gastroenteritis in the United States. J. Infect. Dis. 186(1), 1-7 (2002).
118. Bok K, Abente EJ, Realpe-Quintero M et al. Evolutionary dynamics of GII.4 noroviruses over a 34-year period. J. Virol. 83(22), 11890-11901 (2009).
119. Huang P, Farkas T, Marionneau S et al. Noroviruses bind to human ABO, Lewis, and secretor histo-blood group antigens: identification of 4 distinct strain-specific patterns. J. Infect. Dis. 188(1), 19-31 (2003).
120. Huang P, Farkas T, Zhong W et al. Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J. Virol. 79(11), 6714-6722 (2005).
121. Lindesmith L, Moe C, Lependu J, Frelinger JA, Treanor J, Baric RS. Cellular and humoral immunity following Snow Mountain virus challenge. J. Virol. 79(5), 2900-2909 (2005).
122. Larsson MM, Rydell GE, Grahn A et al. Antibody prevalence and titer to norovirus (genogroup II) correlate with secretor (FUT2) but not with ABO phenotype or Lewis (FUT3) genotype. J. Infect. Dis. 194(10), 1422-1427 (2006).
123. Lindesmith LC, Donaldson E, Leon J et al. Heterotypic humoral and cellular immune responses following Norwalk virus infection. J. Virol. 84(4), 1800-1815 (2010).
124. LoBue AD, Lindesmith LC, Baric RS. Identification of cross-reactive norovirus CD4+ T cell epitopes. J. Virol. 84(17), 8530-8538 (2010).
125. Greenberg HB, Valdesuso J, Kapikian AZ et al. Prevalence of antibody to the Norwalk virus in various countries. Infect. Immun. 26(1), 270-273 (1979).
126. Menon VK, George S, Aladin F et al. Comparison of age-stratified seroprevalence of antibodies against norovirus GII in India and the United Kingdom. PLoS ONE 8(2), e56239 (2013).
127. Gray JJ, Jiang X, Morgan-Capner P, Desselberger U, Estes MK. Prevalence of antibodies to Norwalk virus in England: detection by enzyme-linked immunosorbent assay using baculovirus-expressed Norwalk virus capsid antigen. J. Clin. Microbiol. 31(4), 1022-1025 (1993).
128. Steinberg EB, Mendoza CE, Glass R et al. Prevalence of infection with waterborne pathogens: a seroepidemiologic study in children 6-36 months old in San Juan Sacatepequez, Guatemala. Am. J. Trop. Med. Hyg. 70(1), 83-88 (2004).
129. Jiang X, Matson DO, Velazquez FR et al. Study of Norwalk-related viruses in Mexican children. J. Med. Virol. 47(4), 309-316 (1995).
130. O'Ryan ML, Vial PA, Mamani N et al. Seroprevalence of Norwalk virus and Mexico virus in Chilean individuals: assessment of independent risk factors for antibody acquisition. Clin. Infect. Dis. (4), 789-795 (1998).
131. Cubitt WD, Green KY, Payment P. Prevalence of antibodies to the Hawaii strain of human calicivirus as measured by a recombinant protein based immunoassay. J. Med. Virol. 54(2), 135-139 (1998).
132. Johnson PC, Mathewson JJ, DuPont HL, Greenberg HB. Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J. Infect. Dis. 161(1), 18-21 (1990).
133. Okhuysen PC, Jiang X, Ye L, Johnson PC, Estes MK. Viral shedding and fecal IgA response after Norwalk virus infection. J. Infect. Dis. 171(3), 566-569 (1995).
134. Gray JJ, Cunliffe C, Ball J, Graham DY, Desselberger U, Estes MK. Detection of immunoglobulin M (IgM), IgA, and IgG Norwalk virus-specific antibodies by indirect enzyme-linked immunosorbent assay with baculovirus-expressed Norwalk virus capsid antigen in adult volunteers challenged with Norwalk virus. J. Clin. Microbiol. 32(12), 3059-3063 (1994).
135. Blacklow NR, Cukor G, Bedigian MK et al. Immune response and prevalence of antibody to Norwalk enteritis virus as determined by radioimmunoassay. J. Clin. Microbiol. 10(6), 903-909 (1979).
136. Wyatt RG, Dolin R, Blacklow NR et al. Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J. Infect. Dis. 129(6), 709-714 (1974).
137. Simmons K, Gambhir M, Leon J, Lopman B. Duration of immunity to norovirus gastroenteritis. Emerg. Infect. Dis. 19(8), 1260-1267 (2013).
138. Jiang X, Wang M, Graham DY, Estes MK. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J. Virol. 66(11), 6527-6532 (1992).
139. Herbst-Kralovetz M, Mason HS, Chen Q. Norwalk virus-like particles as vaccines. Expert Rev. Vaccines 9(3), 299-307 (2010).
140. Ball JM, Graham DY, Opekun AR, Gilger MA, Guerrero RA, Estes MK. Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology 117(1), 40-48 (1999).
141. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin. Immunol. 108(3), 241-247 (2003).
142. Atmar RL, Bernstein DI, Harro CD et al. Norovirus vaccine against experimental human Norwalk virus illness. N. Engl. J. Med. 365(23), 2178-2187 (2011).
143. Reeck A, Kavanagh O, Estes MK et al. Serological correlate of protection against norovirus-induced gastroenteritis. J. Infect. Dis. 202(8), 1212-1218 (2010).
144. Czako R, Atmar RL, Opekun AR, Gilger MA, Graham DY, Estes MK. Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus. Clin. Vaccine Immunol. 19(2), 284-287 (2012).
145. El-Kamary SS, Pasetti MF, Mendelman PM et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J. Infect. Dis. 202(11), 1649-1658 (2010).
146. Ramirez K, Wahid R, Richardson C et al. Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers. Clin. Immunol. 144(2), 98-108 (2012).
147. Bok K, Parra GI, Mitra T et al. Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc. Natl Acad. Sci. USA 108(1), 325-330 (2011).
148. LoBue AD, Lindesmith L, Yount B et al. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 24(24), 5220-5234 (2006).
149. Kitamoto N, Tanaka T, Natori K et al. Cross-reactivity among several recombinant calicivirus virus-like particles (VLPs) with monoclonal antibodies obtained from mice immunized orally with one type of VLP. J. Clin. Microbiol. 40(7), 2459-2465 (2002).
150. Parra GI, Bok K, Taylor R et al. Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine 30(24), 3580-3586 (2012).
151. Tamminen K, Lappalainen S, Huhti L, Vesikari T, Blazevic V. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PLoS ONE 8(7), e70409 (2013).
152. LigoCyte Pharmaceuticals I. Bivalent norovirus vaccine study. http://clinicaltrials.gov/ct2/show/NCT01168
153. Lopman BA, Hall AJ, Curns AT, Parashar UD. Increasing rates of gastroenteritis hospital discharges in US adults and the contribution of norovirus, 1996-2007. Clin. Infect. Dis. 52(4), 466-474 (2011).
154. Batz MB, Hoffmann S, Morris JG, Jr. Ranking the disease burden of 14 pathogens in food sources in the United States using attribution data from outbreak investigations and expert elicitation. J. Food Prot. 75(7), 1278-1291 (2012).
155. Bartsch SM, Lopman BA, Hall AJ, Parashar UD, Lee BY. The potential economic value of a human norovirus vaccine for the United States. Vaccine 30(49), 7097-7104 (2012).